MedPath

Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

Phase 4
Completed
Conditions
Glaucoma
Registration Number
NCT00347802
Lead Sponsor
Innovative Medical
Brief Summary

To compare the diurnal curves in patients using bimatoprost 0.03% versus travoprost 0.004% for the treatment of glaucoma or ocular hypertension.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • · Male or female > 18 years of age

    • Naive to treatment or washed off any ocular hypotensive agents
    • Untreated IOP >19 mm Hg
    • Diagnosis of open-angle glaucoma or ocular hypertension
    • Ability to provide informed consent and likely to complete study
Exclusion Criteria
  • · Known contraindication to bimatoprost or travoprost, or any component of any study medication

    • Uncontrolled systemic disease
    • Active ocular disease other than glaucoma or ocular hypertension
    • Required use of ocular medications other than the study medications during the study
    • History of intraocular surgery within the last 3 months
    • Prior discontinuation of any of the study medications for reasons related to efficacy or safety

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Dr. Noecker

🇺🇸

Pittsburgh, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath